Highlights d Human papillomavirus is not necessary for the development of cervical cancer d Hyperactivated YAP1 in cervical epithelia is sufficient to drive cervical carcinogenesis d Synergism between HPV and YAP1 accelerates cervical cancer initiation and progression d Combined targeting of YAP1 and HPV may improve cervical cancer prevention and treatment SUMMARY HPV infections are common in healthy women and only rarely cause cervical cancer, suggesting that individual genetic susceptibility may play a critical role in the establishment of persistent HPV infection and the development of cervical cancer. Here, we provide convincing in vitro and in vivo evidence showing that differential expression and activation of YAP1 oncogene determine individual susceptibility to HPV infection and cervical carcinogenesis. We found that hyperactivation of YAP1 in mouse cervical epithelium was sufficient to induce invasive cervical cancer. Cervical epithelial cell-specific HPV16 E6/E7 and YAP1 double-knockin mouse model demonstrated that high-risk HPV synergized with hyperactivated YAP1 to promote the initiation and progression of cervical cancer. Our mechanistic studies indicated that hyperactivation of YAP1 in cervical epithelial cells facilitated HPV infection by increasing the putative HPV receptor molecules and disrupting host cell innate immunity. Our finding reveals an unconventional mechanism for cervical carcinogenesis.
In Brief
HPV infections are common in healthy women and only rarely cause cervical cancer. He et al. provide evidence that hyperactivation of the YAP1 oncogene can drive cervical cancer initiation and progression. YAP1 hyperactivation in cervical epithelial cells increases the HPV receptors and disrupts host cell innate immunity, facilitating HPV infection.
INTRODUCTION
Cervical cancer is the most common gynecologic cancer and the fourth leading cause of cancer-related death in women worldwide. According to the latest statistics of the International Agency for Research on Cancer (IARC), approximately 527,000 women are diagnosed with cervical cancer, and an estimated 265,000 women die of this disease each year, equal to almost one-tenth of global cancer deaths in women (Torre et al., 2015) . The increased use of the Pap test and intensive implementation of health education programs have reduced cervical cancer death by more than 50% in the United States over the past 40 years. Nevertheless, the National Cancer Institute estimates that 250,000 women are living with cervical cancer in the United States (Howlader et al., 2018) . The treatment for cervical cancer includes surgery, radiation, or concurrent chemoradiation. However, the survival rates of advanced-stage and recurrent cervical cancer patients are still very low. Cervical cancers of advanced stages and distant recurrence are currently considered to be incurable. Effective new therapeutic options are currently not available, because the detailed mechanism or mechanisms underlying cervical cancer development and progression are unclear at present.
Because the majority of cervical cancer patients are positive for human papillomavirus (HPV) DNA, it is widely accepted that all cases of cervical cancer are caused by high-risk HPV (Walboomers et al., 1999) . However, although the lifetime risk for HPV infection is more than 75% (Koutsky, 1997) , only a very small portion of women infected with HPV develop cancers (Kulasingam et al., 2002) , suggesting that HPV alone is not sufficient for the malignant transformation of cervical epithelial cells. The molecular mechanism or mechanisms underlying the tumorigenesis of cervical epithelium are unclear.
The Hippo pathway is an evolutionarily conserved pathway that controls organ development from the fruit fly to mammals (Dong et al., 2007; Mo et al., 2014) . Overall, the upstream core kinases of the Hippo pathway, including FAT1/2/3/4, Nf2, Mst1/2, Sav1, LATS1/2, and MOB1a/b, have been identified as tumor suppressors, while the downstream effectors, mainly YAP1 and TAZ (WWTR1) transcriptional co-activators, have been described as oncoproteins (Pan, 2010; Zanconato et al., 2016) . Our previous studies showed that the Hippo/YAP signaling pathway may play a role in cervical carcinogenesis. We found that YAP1, the major effector of the Hippo signaling pathway, interacted with HPV16 E6 oncoprotein to drive the initiation and progression of cervical cancer (He et al., 2015b) . Very recently, The Cancer Genome Atlas (TCGA) Research Network published the most comprehensive cervical cancer genome, analyzing results after sequencing tissues derived from 228 primary cervical cancers (Cancer Genome Atlas Research Network et al., 2017) . The extended TCGA dataset indicated that a gene cluster with high copy number alterations mostly contained squamous tumors with amplification events involving 11q22 (YAP1, BIRC2, and BIRC3) and 7p11.2 (EGFR). These data strongly support a role of the Hippo/YAP1 pathway in the development of cervical cancer. In the present study, we successfully developed several transgenic mouse models indicating that the Hippo/YAP1 pathway is at the center of cervical carcinogenesis. We found that hyperactivation of YAP1 in the cervical epithelial cells is sufficient to induce cervical squamous cell carcinoma (CVSCC). We also found that hyperactivated YAP1, by upregulating expression of the putative HPV receptors and suppressing innate immunity, facilitates HPV infection of cervical epithelial cells. HPV in turn synergizes with YAP1 to promote the initiation and progression of cervical cancer.
RESULTS

The Hippo/YAP Pathway Is Frequently Dysregulated in Cervical Cancer Patients
To examine the role of the Hippo/YAP pathway in the development of cervical cancer, we first analyzed the genomic data of 191 cervical cancer patients, which were deposited in TCGA (Cancer Genome Atlas Research Network et al., 2017; Cerami et al., 2012) . The results showed that YAP1, the oncogenic effector of the Hippo pathway, was frequently (11%) amplified, while LATS1/2, MST1, and FATs, which are upstream tumor suppressors of the Hippo pathway, were frequently deleted or mutated in cervical cancer patients ( Figure S1A ). Importantly, we found that the rates of overall survival and disease-free survival of 74 patients with amplification of YAP1 or deletion and/or mutation of tumor suppressors (FAT1/2/3/4, MST1/2, LATS1/2) were significantly poorer than in 96 patients without genomic alterations (Figures S1B and S1C), suggesting that dysregulation of the Hippo/YAP pathway in patients is associated with poor outcomes. Consistent with these results, immunohistochemistry (IHC) studies showed that both the immunosignal intensity and positivity of YAP1 protein significantly increased with grades of cervical intraepithelial neoplasia (CIN) (n = 7 for normal control, n = 28 for CIN1, n = 23 for CIN2, n = 29 for CIN3; Figures S2A-S2D ). Cervical cancer tissues from advanced-stage patients had higher expression levels and more nuclear accumulation of YAP1 protein compared with those from early-stage patients (n = 68; Figures S2A-2D ), indicating that the activity of YAP1 was elevated with cancer progression.
Hyperactivation of YAP1 Is Sufficient to Induce Cervical Cancer In Vivo To examine whether hyperactivation of YAP1 plays a role in cervical carcinogenesis, we generated a mouse model with cervical epithelial cell-specific expression of YAP S127A ( Figure 1A ).
In these transgenic mice (hereafter referred to as KRT14-YAP S127A ), the expression of YAP S127A (constitutively active YAP1) was under the control of the keratin 14 (KRT14) promoter and doxycycline (Dox) availability, allowing inducible expression of YAP S127A in mouse cervical epithelial cells ( Figure 1A) . After PCR-based genotyping ( Figure 1B ), Dox-containing water was used to replace the normal drinking water of 3-month-old control (KRT14-rtTA or TRE-YAP S127A alone) and KRT14-YAP S127A mice. We found that high concentration of DOX (2.0 mg/mL) induced hyperplasia of squamous epithelium in multiple organs within 2 weeks, leading to rapid death of these animals (Figure S3) . However, when the concentration of Dox in drinking water was reduced to 0.05 mg/mL, multi-organ hyperplasia was significantly alleviated, but ectopic YAP S127A was still expressed in CVSCCs ( Figure 1E ). As shown in Figure 1F , low concentration of Dox-induced expression of YAP S127A resulted in drastic hyperplasia of cervical epithelial cells within 2 months in KRT14-YAP S127A mice but not in control mice. Most of KRT14-YAP S127A mice developed invasive cervical tumors after induction with 0.05 mg/ML Dox for 6-8 months (Figures 1C, 1D, and 1F) . With the progression of cervical cancer, ureteral obstruction, which is frequently present in advanced human cervical cancer patients, was observed in some KRT14-YAP S127A mice ( Figure 1D ). About 50% of KRT14-YAP S127A mice died after 13 months of induction of YAP S127A expression with Dox (Figure 1G) . IHC analysis indicated that known protein biomarkers currently available for cervical cancer subtype screening (Ki67, P16 INK4A , deltaNp63, EGFR, and Pan KRT) were highly expressed in cervical cancer tissues from the KRT14-YAP S127A mice ( Figure S4 ). No obvious difference was observed in the TP53 protein levels between the control and cancerous cervical tissues ( Figure S4 ). These biochemical features support the pathological conclusion that cancers in KRT14-YAP S127A mice are CVSCC.
YAP1 Facilitates HPV Infection of Cervical Epithelial Cells
Although our animal model showed that hyperactivation of YAP1 is sufficient to induce the development of CVSCC, the strong epidemiological association between HPV infection and cervical (D) A representative image showing the general anatomy of KRT14-rtTA control mice and KRT14-YAP S127A mice. Note the obstruction of the urination system (the red arrow points to an enlarged bladder) caused by ureter blockage due to cervical tumor in KRT14-YAP S127A transgenic mice. (legend continued on next page) cancer implies that HPV oncoproteins are involved in cervical tumorigenesis. HPV primarily infects basal epithelial cells when a wound is created in cervical tissue (Figure 2A ). IHC showed that YAP1 protein was highly expressed in cervical basal cells in human and mouse cervix ( Figure 2B ). This coincidence suggests that high YAP1 in the basal cells may facilitate HPV infection during wound healing process. Indeed, a wound-healing assay using primary cultures of human cervical epithelial cells (hCerECs) showed that in the ''wound'' area, YAP1 was predominately localized to nuclei (active form of YAP1), while in the non-wound area, YAP1 protein was almost evenly distributed in cytoplasm and nucleus of hCerECs ( Figure 2C ). We then used a HPV16 pseudovirion (HPV16 PsV) to examine if YAP1 expression affected HPV infectivity. After incubating hCerECs with HPV16 PsVs (MOI = 2.0) for 72 h, GFP-positive cells were detected in the wound area ( Figure 2D ), but few GFP-positive cells were found in the non-wound area ( Figures 2D and 2E ). The signal intensity of GFP was also much stronger in hCerECs in the wound area ( Figure 2D ). Incubating hCerECs with HPV16 PsVs (MOI = 1.0) for 72 h in the regular two-dimensional (2D) culture results in more GFPpositive cells in hCerEC-YAP and hCerEC-YAP S127A cells compared with hCerEC-MX control cells ( Figures 2F and S5A ). In contrast, knockdown of YAP1 significantly reduced the infectivity of HPV16 PsV in hCerECs after incubating with HPV16 PsV (MOI = 2.0) for 72 h ( Figures 2G and S5B) . Similar results were observed in YAP1 differentially expressed ECT1 cells and SiHa cells ( Figures 2H, 2I , S5C, and S5D). These results provide direct evidence that hyperactivation of YAP1 increases the susceptibility of cervical epithelial cells to HPV infection.
YAP1 Facilitates HPV Infection of hCerEC Cells by Upregulating the Putative HPV Receptors
The specificity and susceptibility of a host cell to viral infection are controlled by the interaction between virus and the putative viral receptor molecules on the host cell membrane (Grove and Marsh, 2011) . Heparan sulfate proteoglycans (HSPGs; such as Syndecan-1), integrin a6 (ITGA6), and epidermal growth factor receptor (EGFR) have been identified as putative HPV receptor molecules (Raff et al., 2013; Surviladze et al., 2012; Yoon et al., 2001) . Interestingly, we found that all examined putative HPV receptor molecules were significantly upregulated in YAP1 hyperactivated hCerECs but downregulated in YAP1-knockdown hCerECs ( Figures 3A and 3B ). Knockdown of ITGA6 in hCerEC-YAP and hCerEC-YAP S127A cells blocked YAP-and YAP S127A -induced increase of HPV16 PsV intake (indicated by GFP signal) in these cells after incubation with HPV16 PsV (MOI = 1.0) for 72 h (Figures 3C and S5E) . Similarly, knockdown of ITGA6 in SiHa cervical cancer cells also inhibited the efficiency of HPV16 PsV infection (MOI = 1.0) ( Figure S5F ). Importantly, we found that hyperactivation of YAP1 also upregulated expression of ITGA6, SDC1, and EGFR in vivo (Figures 3D, S4, and S6) . IHC analyses showed that expression of ITGA6 and SDC1 in the epithelium of the KRT14-YAP S127A mice is significantly increased compared with that of the KRT14-rtTA control mice ( Figure S6 ). These results demonstrate that hyperactivation of YAP1 upregulates the expression of the putative HPV receptors on the membrane of cervical epithelial cells to facilitates HPV infection.
Hyperactivation of YAP1 Interrupts Type I Interferon Production in Cervical Epithelial Cells
Under normal conditions, HPV infection is thought to be cleared up by the immune system. However, under certain pathological conditions, host cell immunity may be compromised, and HPV escapes immune surveillance, leading to establishment of persistent infection and increased risk for cervical cancer in these patients. The innate immune system constitutes the first line of defense against HPV infection (Amador- Molina et al., 2013) . Fluorescent immunocytochemistry in the wound healing model showed that IRF3, one of the major transcription factors controlling production of type I interferons ( Figure S7A ), is negatively associated with YAP1 activity ( Figure 4A ). In non-wound areas of the wound-healing assay, inactive YAP1 was mainly localized to cytoplasm of hCerECs, while IRF3 was localized mainly to nuclei ( Figure 4A ). However, in the ''wound'' area, YAP1 was predominantly translocated to nuclei (activated), while IRF3 was localized predominantly to cytoplasm (inactive form; Figure 4A ). These results suggest that YAP1 may manipulate IRF3 activity to modulate innate immunity in cervical epithelial cells.
(B) Representative images showing the expression of YAP1 (red) in mouse and human normal cervical tissues. Note that YAP1 is expressed mainly in basal cells (arrow and arrowhead) and localized predominantly to the nuclei of these cells in cervical epithelium. Scale bar: 100 mm. (C) Representative images showing cellular localization of YAP1 protein (green) in hCerECs during wound healing. In vitro wound-healing assay showed that in confluent area, YAP1 was localized predominantly in the cytoplasm of hCerECs, while in the ''wound'' area, YAP1 translocated into the nuclei of these cells. Scale bar: 20 mm. (D) Representative images showing that HPV preferentially infected hCerECs in ''wound'' area. hCerECs were incubated in growth media with HPV16 pseudovirions (PsVs; MOI = 2) for 72 h. The infection efficiency of HPV16 PsV in hCerECs is represented by the ratio of GFP-positive cells. Note that the positivity and intensity of GFP signal were localized predominantly to cells in ''wound healing'' area. Scale bar: 100 mm. (E) Quantification results of (D). Each bar represents mean ± SEM (n = 5). ***p < 0.001. (F) Representative images showing HPV16 PsV-derived GFP signal in hCerEC-MX cells (hCerECs transfected with an empty vector as control), hCerEC-YAP cells (hCerECs transfected with a vector expressing wild-type YAP1), and hCerEC-YAP S127A cells (hCerECs transfected with a vector expressing YAP S127A , a constitutively active form of YAP1). Cells were incubated in the growth media with or without HPV16 PsV (MOI = 1) for 72 h. Scale bar: 100 mm. (G) Representative images showing HPV16 PsV-derived GFP signal in hCerEC-CTRL cells (hCerECs transfected with non-targeting scrambled short interfering RNA [siRNA] as control) and hCerEC-siYAP cells (hCerECs transfected with YAP1-specific siRNA). Cells were incubated in growth media with HPV16 PsV (MOI = 1) for 72 h. Scale bar: 100 mm. (H) Representative images showing HPV16 PsV-derived GFP signal in Ect1-MX, Ect1-YAP, and Ect1-YAP S127A cells. Ect1 cells is an immortalized cervical epithelial cell line. Scale bar: 100 mm. (I) Representative images showing HPV16 PsV-derived GFP signal in SiHa-CTRL and SiHa-siYAP cells. SiHa is a cervical cancer cell line. Scale bar: 100 mm. Quantitative data are presented in Figure S5 . Following viral entry, the first step in activating an innate immune response against viral infection is the detection of viral pathogens, which is mediated by the interaction between pattern recognition receptors (PPRs) of host cells and the pathogen-associated molecular patterns (PAMPs) of HPV virions (Stanley, 2012) . Our RT-PCR results suggested that mRNA expression of the well-studied PRRs for HPV, Toll-like receptors (TLRs) TLR2 (Alphs et al., 2008) and TLR4 (Pannone et al., 2016) , was significantly downregulated in YAP S127A -expressing cells ( Figure 4B ). The signal transduction from TLRs to downstream kinase cascades requires the mediation of several adaptor proteins, including myeloid differentiation primary response gene 88 (MYD88) and TIR-domain-containing adaptor-inducing interferon-b (TRIF) (Tartey and Takeuchi, 2017) . The expression of MYD88 and TRIF mRNA was also inhibited by YAP S127A in hCer-ECs ( Figure 4C ). Western blot analysis further confirmed the downregulation of TLR2 and TRIF in hCerECs overexpressing YAP1 ( Figure S8A ). These results indicated that hyperactivation of YAP1 can negatively regulate the viral recognition pathway.
The recognition of HPV PAMPs by PRRs may trigger a series of kinase cascades that subsequently leads to activation and nuclear translocation of IRF1, IRF3, IRF7, and NFkB, which are transcription factors regulating expression of type I interferons (IFNa and IFNb) and cytokines, the key molecules for antiviral immune response (McNab et al., 2015; Takeuchi and Akira, 2009 ). Similar to TLRs in hCerEC-YAP S127A cells, expression of IRF1 and IRF7 genes was also significantly decreased in YAP1-hyperactivated cells ( Figure 4D ). Consistently, knockdown of YAP1 in these cells significantly increased expression of IRF1 and IRF7 mRNA levels ( Figure 4E ). Although the level of IRF3 protein was not significantly affected by YAP1 expression, the level of phospho-IRF3 (active form) was decreased in hCerECs expressing YAP S127A ( Figure S8A ). Immunofluorescent analysis also showed that ectopic expression of YAP1 or YAP S127A resulted in translocation of IRF3 and NFkB1 from nucleus to cytoplasm in hCerECs, suggesting the transcriptional activity of IRF3 and NFkB1 was inhibited in YAP-and YAP S127Aoverexpressed cells (Figures 4F, S8A, and S8B) .
Consistent with in vitro results, critical genes involved in viral recognition signaling, such as TLR2, MYD88, and TBK1, were significantly downregulated in KRT14-YAP S127A mice (Figure 4G) . IHC staining results further demonstrated that in comparison with the control cervical tissues, the cervical epithelial layer of KRT14-YAP S127A mice expressed significantly lower levels of MYD88 and TBK1 ( Figures 4H and S8C ), suggesting that hyperactivation of YAP1 attenuates the innate immune system in vivo.
Hyperactivation of YAP1 Interrupts the IFNRs-JAKs-STATs Signaling Pathway to Inhibit Production of Antiviral ISGs in Cervical Epithelial Cells Normally, the secreted IFNs bind to IFN receptors on adjacent cells, resulting in the activation of the JAK-STAT pathway in these cells ( Figure S7B ). Phosphorylated STAT1 and STAT2 then bind with IRF9 to form a complex called IFN-stimulated gene factor 3 (ISGF3) to initiate the transcription of hundreds of genes that act to block viral infection (Schneider et al., 2014) . The RT-PCR results showed that mRNA expressions of IFNa receptor 2 (IFNAR2), JAK1, JAK2, STAT1, and IRF9 were downregulated in hCerEC-YAP S127A cells (Figures 5A and Figure S9A ), while mRNA expression of IFNAR1 and IRF9 was upregulated in YAP1-knockdown hCerECs ( Figure 5B ). Immunoblotting analysis also detected reduced levels of JAK1, STAT1, phospho-STAT1, and IRF9 proteins in YAP-overexpressed cells ( Figure 5C ). These results indicated that hyper-active YAP1 could inhibit the signal transduction from type I IFNs to ISGF3. Consistent with this, immunofluorescence confocal microscopy showed that compared with control (MX) cells, ectopic expression of YAP1 or YAP S127A not only reduced the signal intensity of total STAT1 and IRF9 but also decreased the immunosignal of nuclear STAT1 and IRF9. Treatment of hCerECs with recombinant IFNa2b (50 IU, 45 min) rapidly induced nuclear accumulation of STAT1 and IRF9 in hCerEC-MX cells, but it failed to do so in hCerEC-YAP and hCerEC-YAP S127A cells ( Figure S9B ). We also noticed that in control cells, IRF9 and STAT1 formed multiple foci in the nucleus. However, the focal pattern of IRF9 and STAT1 was diminished in YAP S127A -expressed cells ( Figure S9B) , indicating that the transcriptional activity of ISGF3 complex was inhibited by YAP1 hyperactivation. Similar results were observed in wound-healing assay ( Figure S10 ).
Type I interferons (mainly IFNa and IFNb) can induce expressions of a large spectrum of interferon-stimulated genes (ISGs) in virus-infected cells as well as neighbor cells. IFN-induced ISGs are involved in almost all key steps of antiviral effects in host cells, including inhibition of virus entry, blockade of virus replication, and obstruction of viral egress (Schneider et al., 
2014
). As expected, expression of genes encoding ISGs that directly inhibit virus infection, such as MX1 (myxovirus resistance 1), ISG15, APOBEC3G (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G), OAS1 (2 0 -5 0 -oligoadenylate synthetase 1), TRIM5 (tripartite motif family protein 5), and IFI44L, was significantly downregulated in YAP S127A -expressed hCerECs (Figures 5A and S9A) . Consistently, knockdown of YAP1 in hCerECs upregulated many antiviral ISGs, such as MX1, CH25H, IFITMs (inhibitors of virus entry), and APOBEC3G, OAS1/2, ISG15, and IFI44L (suppressors of virus translation and replication) ( Figures 5B and S11A) . Taken together, these results provide strong evidence that constitutive activation of YAP1 can suppress the IFNaRs-JAKs-STATs pathway and reduce the production of antiviral ISGs.
To further examine the role of hyperactivated YAP1 on the IFNinduced antiviral effect, we pretreated control and YAP-overexpressing hCerECs with recombinant IFNa2b (50 IU) for 24 h and then incubated these cells with HPV16 PsVs (MOI = 1.0) for 72 h. IFNa2b treatment resulted in a significant decrease in the number of GFP-positive cells in control hCerECs (Figures 5D and S11B). However, IFNa2b had no effect on the positivity and intensity of GFP signal in hCerEC-YAP and hCerEC-YAP S127A cells ( Figures 5D and S11B) . These results, combined with the above data, suggested that hyperactivation of YAP1 in cervical epithelial cells not only suppresses the production of type I IFNs but may also diminish the antiviral effects of IFNs.
Consistent with in vitro results, expression of genes encoding the core components of the JAK-STAT/IRF9 pathway, such as JAK1, STAT1, and IRF9, were also significantly reduced in KRT14-YAP S127A mice ( Figure 5E ). IHC staining results further demonstrated that in comparison with the control cervical tissues, cervical epithelial layer of KRT14-YAP S127A mice expressed significantly lower levels of JAK1 and IRF9 proteins (Figures 5F and S11C). MX1 and ISG15, the two best characterized antiviral ISGs, were diminished at both transcriptional (mRNA) and protein levels in KRT14-YAP S127A mice (Figures 5E, 5F , and S11C). These results provide evidence that hyperactivation of YAP1 attenuates the innate immune system in vivo.
HPV Synergizes with YAP1 to Promote Carcinogenesis of Cervical Epithelium In Vivo
Although hyperactivation of YAP1 is sufficient to induce development of cervical cancer, it generally took 6-8 months to observe invasive cancer in the cervical epithelium under constitutive induction of YAP1 expression with low concentration of Dox.
The observation that hyperactivation of YAP1 induced expression of the putative HPV receptors and suppression of innate immune system in cervical epithelial cells indicates that HPV and YAP1 might function in a synergic manner to drive the development of cervical cancer. To examine the potential synergism of hyperactivated YAP1 and HPV oncoproteins, we used KRT14-E6 (HPV16) mice, KRT14-E7 (HPV16) mice (Riley et al., 2003) , and KRT14-YAP S127A mice to create two new transgene mouse models, KRT14-E6-YAP S127A and KRT14-E7-YAP S127A mice ( Figures 6A and 6B) . These mice express both HPV oncoprotein E6 (or E7) (under control of KRT14 promoter) and YAP S127A (under control of KRT14 and Dox induction) in cervical epithelial cells. Consistent with previous reports (Riley et al., 2003) , KRT14-E6 and KRT-E7 mice rarely developed cervical cancer without exposure to a relatively high concentration of estrogen, even after treatment with a low concentration of Dox for 1.5 years. Most KRT14-YAP S127A mice, as shown before, developed cervical cancer after 6-8 months of Dox induction. However, we found that most of KRT14-E6-YAP S127A and KRT14-E7-YAP S127A mice developed invasive cervical cancer within 4 months of induction ( Figure 6C ). Compared with KRT14-YAP S127A mice, cancer progression in KRT14-E6-YAP S127A and KRT14-E7-YAP S127A mice was much faster than that in KRT14-YAP S127A mice. After induction with a low concentration of Dox for 9 months, about 30% of KRT14-YAP S127A mice were dead (or euthanized because of urethral obstruction). However, the death rate in KRT14-E6-YAP S127A and KRT14-E7-YAP S127A mice reached 60% and 75%, respectively ( Figures  6D and 6E ). Cancer cells in the cervical tissue of KRT14-E6/E7-YAP S127A mice were more invasive and aggressive than in KRT14-YAP S127A mice ( Figure 6C ). These in vivo data strongly support our hypothesis that HPV synergizes with hyperactivated YAP1 to drive initiation and progression of cervical cancer.
DISCUSSION
Novel Mouse Models Suggest that HPV Is Not a Necessary Cause of Cervical Cancer
The recognition of HPV infection as a major risk factor for cervical cancer has been considered a breakthrough in cancer research in the past three decades. During the 1990s, epidemiological studies, supported by molecular technologies, concluded that persistent high-risk HPV (hrHPV) infection was a necessary cause of cervical cancer, implying that cervical cancer does not and will not form in the absence of persistent HPV infection (B) Quantitative data showing mRNA levels of YAP1 and genes of the core components of the IFNR/JAK/STAT antiviral pathway in hCerEC-CTRL cells (cells transfected with scrambled non-target siRNA) and hCerEC-siYAP cells (cells transfected with YAP1-specific siRNA). Each bar represents the mean ± SEM (n = 4). *p < 0.05, **p < 0.01, and ***p < 0.001. (C) Representative blots from three independent experiments showing expression and activation of key proteins and kinases in the JAK/STAT/IRF9 pathway in hCerEC-MX (control), hCerEC-YAP, and hCerEC-YAP S127A cells. (D) Representative images showing HPV16 PsV-derived GFP signal in hCerEC-MX, hCerEC-YAP, and hCerEC-YAP S127A cells in the presence or absence of recombined human interferon alpha 2b (IFNa2b). GFP signal indicates the infection efficiency of HPV16 PsV in these cells. Scale bar: 100 mm. Quantitative results of GFP signal is presented in Figure S11B . (E) RT-PCR analyses showing expression of JAK1, IRF9, STAT1, and MX1 mRNA in cervical tissues from control KRT14-rtTA (CTRL) and KRT14-YAP S127A mice. Each bar represents the mean + SEM (n = 4). ***p < 0.001. (F) Representative images showing expression of JAK1, IRF9, MX1, and ISG15 proteins in cervical tissues from KRT14-rtTA control (CTRL) and KRT14-YAP S127A mice. Protein expression was determined using the peroxidase-based immunohistochemistry. The nuclei were counterstained with hematoxylin. Scale bar: 250 mm. 5 and 7) , and KRT14-E7-YAP S127A (lane 6) transgenic mice.
(legend continued on next page) (Schiffman and Castle, 2003; Walboomers et al., 1999) . However, although the estimated lifetime risk for HPV infection can be 75% (Koutsky, 1997) , the lifetime risk for developing cervical cancer is only 0.68% (Howlader et al., 2012) . Moreover, cervical cancer occurs many years after HPV infection (Howlader et al., 2012; Weaver, 2006) . In addition, cervical cancer shows very high intratumor heterogeneity (Cancer Genome Atlas Research Network et al., 2017; Lyng et al., 2004) . These observations indicate that exposure to HPV alone is insufficient for cervical cancer development (Perez-Plasencia et al., 2008; Uren et al., 2005) . Animal studies showed that cervical epithelial specific expression of HPV16 E6, E7, or their combination did not induce cervical cancer without support of exogenous estrogen (Brake and Lambert, 2005; Riley et al., 2003) . Accumulating evidence suggests that the presence of a persistent hrHPV infection risk is not sufficient to immortalize and transform the epithelial cells of the host (Gatza et al., 2005; Roden and Wu, 2006) . Currently, it is widely accepted that that persistent HPV infection is a necessary but insufficient cause for the carcinogenesis of cervical epithelium (National Cancer Institute, 2018) . Existing evidence indicates that the presence of genetic and epigenetic alterations is necessary for the carcinogenesis of cervix, although the specific alteration or alterations are still not clear. In the present study, we provide in vitro and in vivo evidence to show that pathological alterations of the Hippo/YAP signaling pathway are sufficient to induce cervical cancer, regardless HPV infection. However, the synergism between HPV oncoprotein and YAP1 oncogene significantly accelerates tumorigenesis of the cervix.
Central Role and Functional Mechanism of YAP1 in Cervical Cancer Development
The role of the Hippo/YAP1 signaling pathway in cancer development has been intensively studied over the past 10 years (Mo et al., 2014; Pan, 2010; Yu et al., 2015; Zanconato et al., 2016) . Both in vitro and in vivo evidence indicates that dysregulation of the Hippo signaling cascade and activation of protooncogene YAP1 are linked to many human cancers, including cancers of the skin, lung, colon, breast, kidney, liver, and ovary (Gomez et al., 2014; He et al., 2015a; Lee et al., 2010; Steinhardt et al., 2008) . Cross-cancer genomic analyses based on TCGA datasets showed that the most frequent genomic alteration of the Hippo/YAP1 pathway occurs in the cervical carcinoma. This observation is supported by recent genome-wide screening by TCGA, which also showed that the copy number of genes in chromosome 11q22 was frequently amplified in CVSCC. Interestingly, YAP1 and its downstream target genes BACR2 and BACR3 are located in this area (Cancer Genome Atlas Research Network et al., 2017) . On the basis of DNA methylation status, the authors identified a sub-group of cervical cancer that had epithelial-mesenchymal transition (EMT) features and was associated with the worst survival outcomes. Importantly, they found that YAP1 gene was amplified in cancer cells derived from the EMT cluster, and YAP1 protein was the most significantly differentially expressed protein that distinguished the EMT cluster from other sub-groups (Cancer Genome Atlas Research Network et al., 2017) . We mined TCGA cervical cancer datasets and found that besides YAP1 amplification, the upstream genes of the Hippo pathway, including MST1, LATS1/2, and FAT1/2/3/4, which negatively regulate YAP1 activity, were frequently deleted and/or mutated in cervical cancer patient samples. Our previous data also showed that hyperactivation of YAP1 in hCerECs induced malignant transformation of these cells (He et al., 2015b) . The development of CVSCC in KRT14-YAP S127A mice, which are HPV negative, strongly supports the notion that the disrupted Hippo pathway and the subsequent hyperactivation of YAP1 represent a novel mechanism of cervical carcinogenesis. The precise mechanism for the Hippo/YAP pathway regulating cervical cancer cell growth remains largely undefined. Our recent study demonstrated that overexpression of YAP1 in cervical cancer cells can overcome the contact inhibition-induced cell growth inhibition, promote cell cycle progression, and significantly stimulate cervical cancer cell growth in vitro and in vivo (He et al., 2015b) . Knockdown of YAP1-negative regulators LATS1/2 resulted in a significant increase in the cervical epithelial cell proliferation. Moreover, we found that the EGFR pathway was involved in YAP1-induced cervical cancer cell proliferation and migration. Activation of YAP1 in cervical cancer cells significantly stimulated the expression of EGFR and its ligands TGFa and AREG. In turn, TGFa and AREG, via EGFR signaling, suppressed the Hippo pathway and activated YAP protein (dephosphorylated LATS1, MOB1, and YAP1) to promote cervical cancer cell growth (He et al., 2015b) . The existence of this Hippo/YAP and EGFR feedback loop in human cervical cancer suggested that the combined targeting of the Hippo/YAP and EGFR pathways may be an efficient way to treat cervical cancer.
Previous studies showed that HPV infection is a necessary cause of cervical cancer. In reality, following infection, the majority of HPV becomes undetectable within 1-2 years, and the virus is cleared spontaneously by the immune system. Nevertheless, persistent HPV infection happens in some high-risk individuals and increases the risk for cervical cancer in these women. The mechanism by which HPV evades immune surveillance in these patient is not clear. Some reports suggest that HPV modifies the innate immune system in the host cells, leading to the failure of virus clearance and persistent HPV infection (Scott et al., 2001; Westrich et al., 2017) . However, this modification requires HPV (C) Representative images showing histology of cervical tissues (H&E staining) collected from control, KRT14-E6/E7, KRT14-YAP S127A , KRT14-E6-YAP S127A , and KRT14-E7-YAP S127A mice after induction of YAP S127A gene expression with doxycycline in drinking water for 4-5 months. (D) Kaplan-Meier survival curves showing the overall survival rates of control mice (control, n = 12), KRT-14-YAP S127A mice (YAP S127A , n = 14), KRT14-E6 mice (E6, n = 13), and KRT14-E6-YAP S127A mice (E6+YAP S127A , n = 12) after inducing expression of transgenes with 0.05 mg/mL doxycycline (in drinking water). (E) Kaplan-Meier survival curves showing the overall survival rates of control mice (control, n = 9), KRT-14-YAP S127A mice (YAP S127A , n = 14), KRT14-E7 mice (E7, n = 7), and KRT14-E7-YAP S127A mice (E7+ YAP S127A , n = 8) after inducing expression of transgenes with 0.05 mg/mL doxycycline (in drinking water). (F) A schematic diagram showing the proposed mechanism by which hyperactivated YAP1 and high-risk HPVs synergize to drive the initiation and progression of cervical cancer. E6 and E7 oncogene expression, which happens after HPV initial infection. Therefore, unknown alterations in the defense system of the vulnerable individuals may contribute to the establishment of the persistent HPV infection. In the present study, we found that hyperactivation of YAP1 may be a major contributor to the HPV persistent infection. First of all, results in the present study showed that hyperactivated YAP1 upregulated putative HPV receptor molecules such as ITGRA6, SDC1, and EGFR, which may facilitate the HPV entry process during early stage of HPV infection. Second, we found that hyperactivation of YAP1 in cervical epithelial cells downregulated key components of viral recognition by the innate immune system. We observed that TLR2 and TLR4, well-studied PRRs, as well as their adaptor proteins MYD88 and TRIF, were inhibited, which could exacerbate HPV infection. Third, we found that ectopic expression of YAP S127A inhibited the expression and activation of transcriptional factors that are critical for the production of type I IFNs, including IRF1, IRF3, and IRF7, resulting in decreases of IFNA1, IFNB1, and IFNE in hCerECs. These IFNs can activate intracellular antiviral programs and play a key role in the development of innate and adaptive immune responses. Finally, we observed that the expression and activation of key components of the type I IFN pathway, including IFNAR2, JAK1, STAT1, and IRF9, were broadly inhibited by expression of YAP S127A in cervical epithelial cells. Inhibition the IFNAR2/JAK1/STAT1 signaling pathway resulted in massive downregulation of antiviral ISGs, including MX1, CH25H, and IFITMs (inhibitors of virus entry) and APOBEC3G, OAS1, ISG15, and IFI44L (suppressors of virus translation and replication). More important, the inhibition of innate antiviral pathways by YAP was confirmed in studies with the K14-YAP S127A transgenic mouse. Therefore, the present studies indicate that disruption of the Hippo pathway and subsequent activation of YAP1 in the cervical epithelial may result in defective innate antiviral immunity, which may allow HPV to escape immune surveillance, leading to persistent HPV infection. Consistent with this observation, two research groups in China recently reported that YAP1 negatively regulated the production of type I interferon by suppressing TBK1 activity Wang et al., 2017) . In the Drosophila model, hyperactivation of Yorkie (YAP in mammals) also led to the decrease of antimicrobial peptides in adipose tissues, suggesting that YAP1 regulation of innate immunity is a conserved mechanism of pathological immune suppression (Liu et al., 2016) . These data suggest that enhancing HPV infection may represent a new mechanism for YAP1 to control cervical cancer development.
Identification of the Hippo/YAP Pathway as a Major Player in Cervical Cancer Development Does Not Reduce the Importance of hrHPV in Cervical Tumorigenesis
Although our transgenic mouse model demonstrates that HPV infection is not a necessary event for the development of CVSCC, our present data, plus previous numerous reports, still support the notion that hrHPV infection, especially in vulnerable populations, greatly increases the risk for cervical cancer. Therefore, identification of the Hippo/YAP pathway as a major player in cervical carcinogenesis does not reduce the importance of hrHPV in the development of cervical cancer. Our data clearly indicate that hyperactivation of YAP1 increased viral infectivity and suppressed innate immunity, two events that greatly increase the susceptibility of cervical epithelial cells to HPV infection and facilitate the establishment of persistent HPV infection in these cells. Although HPV alone is not sufficient to induce malignant transformation of cervical epithelial cells, expression of HPV oncoproteins E6 and E7 leads to inactivation of critical tumor suppressors such as TP53 and RB1 in many types of cells (Dyson et al., 1989; Scheffner et al., 1990; White et al., 2016) . Inactivation of TP53 and RB1 can lead to extension of cell life (via suppression of senescence) and even induce immortal phenotype in cervical epithelial cells (Liu et al., 2018) , paving the way for malignant transformation of HPV-infected cells by an oncogenic signal (such as hyperactivation of YAP1). Moreover, we have shown that HPV can prevent proteinase-dependent degradation of YAP1 protein, which maintains high levels of YAP1 protein in HPV-infected cervical epithelial cells. Most important, we found that HPV E6 protein suppressed Hippo pathway in the cervical epithelial cells (He et al., 2015b) . Clearly, HPV synergizes with hyperactivated YAP1 to drive carcinogenesis of cervix. Introduction of HPV16 E6 and E7 oncoproteins significantly promoted cervical carcinogenesis of KRT14-YAP S127A cells, indicating that synergetic function between YAP1 and HPV does exist during cervical tumorigenesis. Therefore, the current HPV vaccination program, which has been shown to be very effective in preventing selected types of HPV (Baldur-Felskov et al., 2014; Sankaranarayanan, 2015) , may greatly reduce infection by HPV and carcinogenesis of the cervix in women in the near future.
In conclusion, the in vitro and in vivo results from the present study show that YAP1, the major effector of the Hippo pathway, plays a central role in the development of cervical cancer. Hyperactivation of YAP1 is sufficient to induce malignant transformation of cervical epithelial cells and development of invasive cervical cancer in mouse models. Disruption of the Hippo pathway and subsequent activation of YAP1 in cervical epithelial cells may facilitate the establishment of persistent HPV infection by upregulating putative HPV receptor molecules and suppressing host cell innate immunity. Together with our previous observations that HPV16 E6 protein is able to suppress the Hippo pathway (thereby activating YAP1) and prevent YAP1 from proteasome-mediated degradation, we conclude that the interaction between the Hippo/YAP pathway hrHPV is a key player in cervical carcinogenesis. The present findings are expected to influence current cervical cancer preventive screening, early detection, and treatment. The current HPV vaccination program may greatly reduce infection by HPV and carcinogenesis of the cervix in women in the near future. The novel mouse models developed in this study provide new tools for further investigation of cervical cancer initiation and progression.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Model Studies Mouse model handling and animal experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the University at Nebraska Medical Center (UNMC) and Massachusetts General Hospital (MGH). KRT14-rtTA (FVB-Tg(KRT14-rtTA) F42Efu/J, #008099) mice were from The Jackson Laboratory. These mice express the reverse tetracyclinecontrolled transactivator (rtTA) protein in basal cells of stratified epithelium under control of the human keratin 14 (KRT14) gene promoter (Nguyen et al., 2006) . The TRE-YAP S127A mice were from Dr. Fernando Camargo's lab (Boston Children's hospital). These mice express a constitutively active form of YAP1 protein (YAP S127A ) under the control of a tetracycline regulatory element (TRE) (Camargo et al., 2007) . The KRT14-E6 and KRT14-E7 mice, which express HPV16 E6 and HPV16 E7 protein under control of KRT14 promoter, respectively, were from Dr. Lambert's laboratory (Herber et al., 1996; Song et al., 1999) . Mouse breeding schemes were shown in Figures 1A and 6A . Genotyping was performed using RT-PCR technique and tail tissue. The genomic DNA in tails was extracted using DirectPCR Lysis Reagent (#102-T) from Viagen Biotech Inc. (Los Angeles, CA). Briefly, tail tissue was lysed in a single-tube with 250ml DirectPCR Lysis and 5ml 20mg/ml Proteinase K (Sigma, #p6556) at 55 C for 24 hours followed by incubating at 85 C for 1 hour. After centrifuging, clear lysate (0.75 ml) was directly used for 20 ml PCR reaction. Primers for genotyping and expected size of each gene are listed in Table S1 . Female mice were used for cervical cancer modeling. All control, KRT-14-YAP S127A , KRT14-E6/E7, and KRT14-E6/E7-YAP S127A transgenic mice were treated with 0.05 mg/mL Dox in drinking water (long-term treatment) or 2 mg/mL Dox in drinking water (2-week short-term treatment) to induce the expression of transgenes when they were three months old. Mice were euthanized and recorded as dead if they showed serious illnesses (dysuria, wasting, or sluggishness) (Herber et al., 1996; Song et al., 1999) N/A KRT14-E7 mice Dr. Lambert's laboratory (Herber et al., 1996; Song et al., 1999) N/A Oligonucleotides Primers for qRT-PCR, see Table S1 This Paper N/A Primers for genotyping, see and incurable. Euthanasia was recommended by an experienced veterinarian in the animal core facility if tumor-carrying mice were incurable and suffering more than moderate stress. Mouse tissues were collected and processed for preparation of protein, RNA, frozen and paraffin sections after euthanasia.
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were repeated at least four times unless otherwise noted. Data are presented as mean ± SEM. Statistical analysis was conducted, and graphs were made with GraphPad Prism 7.04 (GraphPad Software, Inc. La Jolla, CA). Data were analyzed for significance using Student's t test (two groups) or one-way ANOVA with Tukey's post hoc tests (multiple groups). A value of p < 0.05 was considered statistically significant.
